12 completed, 4 not yet recruiting, 4 recruiting, 3 active not recruiting. 30 Phase 3, 13 Phase 2.
Follow Vitiligo: new trials by email Literature Review of Vitiligo trials Research Report on Vitiligo
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Two Trials to Evaluate TEV-53408 in Participants With Non-Segmental Vitiligo TEV-53408 Dose A, TEV-53408 Dose B, Placebo - Vitiligo | Phase 2 / Phase 3 | Not yet recruiting | Teva Branded Pharmaceutical Products R&D LLC | 1020 | 2026-11-16 | 2026-11-05 |
| Mitochondrial Network Modulation Approach Using Hyperbaric Oxygen (HBO) Therapy and Nb-UVB for Treating Vitiligo OXYGENE MEDICINAL LIQUIDE AIR PRODUCTS MEDICAL - Vitiligo Vulgaris | Phase 2 / Phase 3 | Not yet recruiting | Centre Hospitalier Universitaire de Nice | 5 | 2026-09-01 | 2026-06-05 |
| A Phase III Clinical Study to Evaluate the Efficacy and Safety of MH004 Ointment in Non-segmental Vitiligo MH004 1.0% Ointment, MH004 Placebo Ointment - Vitiligo | Phase 3 | Recruiting | Minghui Pharmaceutical (Hangzhou) Ltd | 405 | 2026-08-04 | 2026-08-11 |
| Efficacy and Safety of Ruxolitinib Cream in Chinese Children Aged 2-11 Years With Non-segmental Vitiligo Ruxolitinib 1.5% Cream BID - Vitiligo | Phase 3 | Not yet recruiting | The Children's Hospital of Zhejiang University School of Medicine | 20 | 2026-06-01 | 2026-05-19 |
| Evaluation of Crisaborole 2% Versus Tacrolimus 0.1% Each Combined With Excimer Light in the Treatment of Stable Non-segmental Facial Vitiligo: a Prospective Randomized Controlled Study. Crisaborole 2% topical ointment, tacrolimus 0.1%, Excimer Light therapy - Vitiligo, Non-Segmental Vitiligo (NSV) | Phase 3 | Recruiting | Cairo University | 35 | 2026-05-15 | 2026-10-29 |
| Comparative Efficacy of hUCMSC-Secretome Delivered Via Microneedling and Intradermal Microinjection as Adjuvant Therapy to NB-UVB in Nonsegmental Vitiligo: A Quasi-Experimental Study NB-UVB combined with microneedling and topical 10% secretome, receives NB-UVB combined with intradermal secretome injection, NB-UVB alone - Vitiligo | Phase 2 / Phase 3 | Not yet recruiting | Yohanes Firmansyah, dr, MH, MM | 150 | 2026-03-18 | 2026-04-03 |
| Topical Ruxolitinib for Face and Neck Vitiligo of Adult Chinese Patients Refractory to Topical Tacrolimus Ruxolitinib Cream 1.5%, Aqueous cream - Vitiligo | Phase 2 / Phase 3 | Recruiting | Hospital Authority, Hong Kong | 20 | 2024-11-29 | 2024-12-05 |
| Vitiligo, New Treatment and Serum s100B Baricitinib, oral mini pulse, Narrow Band UVB Treatment - Vitiligo, Generalized | Phase 2 / Phase 3 | Recruiting | South Valley University | 50 | 2024-10-02 | 2025-01-10 |
| A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo Ritlecitinib, Ritlecitinib 100 mg, Placebo - Vitiligo | Phase 3 | Active not recruiting | Pfizer | 394 | 2024-01-19 | 2026-09-28 |
| A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo Upadacitinib, Placebo, NB-UVB (narrow-band ultraviolet B) Phototherapy - Vitiligo | Phase 3 | Active not recruiting | AbbVie | 614 | 2023-12-19 | 2026-06-09 |
| A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo Afamelanotide and NB-UVB Light, NB-UVB Light - Vitiligo | Phase 3 | Active not recruiting | Clinuvel, Inc. | 200 | 2023-10-11 | 2025-07-08 |
| Comparative Study Between Topical 5-fluorouracil and Latanoprost in Vitiligo. Latanoprost 0.005% Ophthalmic Solution, 5Fluorouracil - Vitiligo | Phase 2 / Phase 3 | Completed | South Valley University | 40 | 2022-03-15 | 2023-07-11 |
| Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo ruxolitinib, Vehicle - Vitiligo | Phase 3 | Completed | Incyte Corporation | 458 | 2020-09-24 | 2025-08-14 |
| Assess the Efficacy and Safety of SHR0302 Ointment in Adult Patients With Vitiligo Low Dose SHR0302 Ointment BID, High Dose SHR0302 Ointment BID, Placebo Comparator: Vehicle - Vitiligo | Phase 2 / Phase 3 | Terminated | Reistone Biopharma Company Limited | 75 | 2020-01-29 | 2022-07-13 |
| Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) Ruxolitinib cream, Vehicle - Non-segmental Vitiligo | Phase 3 | Completed | Incyte Corporation | 344 | 2019-10-03 | 2025-08-22 |
| Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1) Ruxolitinib cream, Vehicle - Non-segmental Vitiligo | Phase 3 | Completed | Incyte Corporation | 330 | 2019-09-20 | 2025-08-22 |
| Microneedling and Latanoprost in Acrofacial Vitiligo Latanoprost, Microneedling - Vitiligo | Phase 2 / Phase 3 | Unknown | Sohag University | 70 | 2018-09-01 | 2018-08-28 |
| Efficacy of Tacrolimus in Adults With Facial Non-segmental Vitiligo - VITAC tacrolimus, Placebo - Vitiligo | Phase 3 | Completed | University Hospital, Bordeaux | 42 | 2016-02-23 | 2021-04-19 |
| Assessing the Efficacy of Needling With or Without Corticosteroids in the Repigmentation of Vitiligo Needling, Triamcinolone - Vitiligo | Phase 2 / Phase 3 | Terminated | Rutgers, The State University of New Jersey | 22 | 2014-09-01 | 2017-07-25 |
| Evaluation of Non-cultured Epidermal Cellular Grafting vs Hyaluronic Acid for Repigmenting Vitiligo and Piebaldism VITICELL, PLACEBO - Vitiligo, Piebaldism | Phase 3 | Completed | Laboratoires Genévrier | 38 | 2014-04-29 | 2019-10-14 |
Showing 20 of 30. Sign in to see all of them.
Facies (1) · Piebaldism (1) · Pigmentation Disorders (1)
Hypopigmentation (30) · Skin Diseases (30) · Skin and Connective Tissue Diseases (30) · Pigmentation Disorders (29) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Albinism (1) · Amino Acid Metabolism, Inborn Errors (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Disease Attributes (1) · Eye Diseases, Hereditary (1) · Genetic Diseases, Inborn (1) · Metabolic Diseases (1) · Metabolism, Inborn Errors (1) · Nutritional and Metabolic Diseases (1)
Latanoprost (2) · Ointments (2) · Percutaneous Collagen Induction (2) · Tacrolimus (2) · ruxolitinib (2) · Cell Transplantation (1) · Cell- and Tissue-Based Therapy (1) · Fluorouracil (1) · Lasers, Excimer (1) · Ophthalmic Solutions (1) · Phototherapy (1) · Secretome (1) · Transplantation (1) · Triamcinolone (1) · Triamcinolone Acetonide (1)
Centre Hospitalier Universitaire de Nice (5) · Incyte Corporation (3) · Henry Ford Health System (2) · South Valley University (2) · AbbVie (1) · Ache Laboratorios Farmaceuticos S.A. (1) · Cairo University (1) · Clinuvel, Inc. (1) · Hospital Authority, Hong Kong (1) · Istituti Fisioterapici Ospitalieri (1) · Laboratoires Genévrier (1) · Minghui Pharmaceutical (Hangzhou) Ltd (1) · Oslo University Hospital (1) · Pfizer (1) · Reistone Biopharma Company Limited (1)
France (12) · United States (9) · Bulgaria (5) · Canada (5) · China (5) · Germany (5) · Italy (5) · Poland (5) · Spain (5) · Egypt (3) · Netherlands (3) · Belgium (2) · Japan (2) · South Korea (2) · United Kingdom (2)
Kathleen Butler, MD (3) · Iltefat H Hamzavi, MD (2) · Babar Rao, MD (1) · Eli Johanne Nordal, MD (1) · Hassan M Ibrahim, professor (1) · Hossein Baharvand, PhD (1) · Mauro Picardo, MD (1) · Michael Jansen Politan (1) · Nanja Van Geel, Pr (1) · Nasser Aghdami, MD., PhD (1)
PMID 41125994, PMID 36260792, PMID 40156697, PMID 20364383, PMID 33549606, PMID 39078582, PMID 42171987, PMID 42594914
2019 (2), 2023 (2)